As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
HOME > COMMENTARY
COMMENTARY
-
Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
-
Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
-
Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
-
Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
-
Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
-
MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
Survey Hints LLP New Coverage Rule Could Push Generic Switches for Cancer Drugs, Pediatric Meds
October 8, 2024
-
LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
-
Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
-
Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
-
Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
ページ
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…